We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
Cap. Flow
-$803K
Cap. Flow %
-0.33%
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11

Top Buys

Rank Stock Value
1
BKCC
BlackRock Capital Investment Corporation
BKCC
+$673K
2
ZLAB icon
Zai Lab
ZLAB
+$472K
3
SCM icon
Stellus Capital Investment Corp
SCM
+$422K
4
DRD
DRDGold
DRD
+$415K
5
OXLC
Oxford Lane Capital
OXLC
+$359K

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$1.16M
2
RUBY
Rubius Therapeutics, Inc
RUBY
+$664K
3
BNTX icon
BioNTech
BNTX
+$663K
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$645K
5
PRTA icon
Prothena Corp
PRTA
+$590K

Sector Composition

Rank Sector Weight
1 Healthcare 27.38%
2 Real Estate 18.81%
3 Energy 13.29%
4 Materials 10.7%
5 Utilities 10.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
351
Cogent Biosciences
COGT
$6.91B
$199K 0.08%
24,554
-3,547
-13% -$30K
PLRX icon
352
Pliant Therapeutics
PLRX
$66.9M
$198K 0.08%
6,799
-4,151
-38% -$129K
MORF
353
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$198K 0.08%
3,442
-5,486
-61% -$302K
PRAX icon
354
Praxis Precision Medicines
PRAX
$8.8B
$197K 0.08%
+720
New +$258K
QURE icon
355
uniQure
QURE
$2.63B
$197K 0.08%
6,411
-56
-0.9% -$1.88K
KRTX
356
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$197K 0.08%
1,728
-1,458
-46% -$170K
CTMX icon
357
CytomX Therapeutics
CTMX
$708M
$196K 0.08%
30,896
-7,125
-19% -$55.5K
MTEM
358
DELISTED
Molecular Templates, Inc.
MTEM
$196K 0.08%
1,670
-280
-14% -$36.6K
STOK icon
359
Stoke Therapeutics
STOK
$1.83B
$195K 0.08%
5,786
+425
+8% +$15K
KLRS
360
Kalaris Therapeutics
KLRS
$85.2M
$195K 0.08%
428
+103
+32% +$53.2K
ORTX
361
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$195K 0.08%
4,447
-2,154
-33% -$120K
IGMS
362
DELISTED
IGM Biosciences
IGMS
$194K 0.08%
2,328
-1,106
-32% -$81.9K
LITS
363
Lite Strategy Inc
LITS
$33.2M
$194K 0.08%
3,410
-1,776
-34% -$114K
APLT
364
DELISTED
Applied Therapeutics
APLT
$192K 0.08%
9,247
-3,191
-26% -$60.4K
CUE icon
365
Cue Biopharma
CUE
$137M
$192K 0.08%
548
-187
-25% -$72.5K
DNTH icon
366
Dianthus Therapeutics
DNTH
$5.71B
$192K 0.08%
+1,230
New +$226K
VSTM icon
367
Verastem
VSTM
$534M
$192K 0.08%
3,941
-7,084
-64% -$295K
VXRT
368
DELISTED
Vaxart
VXRT
$192K 0.08%
25,589
-13,328
-34% -$93.1K
RUBY
369
DELISTED
Rubius Therapeutics, Inc
RUBY
$192K 0.08%
7,868
-26,528
-77% -$664K
PRLD icon
370
Prelude Therapeutics
PRLD
$310M
$190K 0.08%
+6,622
New +$236K
KALV
371
DELISTED
KalVista Pharmaceuticals
KALV
$189K 0.08%
+7,893
New +$207K
HGEN
372
DELISTED
HUMANIGEN, INC.
HGEN
$189K 0.08%
10,901
-14,205
-57% -$259K
KDNY
373
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$188K 0.08%
+13,299
New +$213K
EVLO
374
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$188K 0.08%
+685
New +$173K
AKRO
375
DELISTED
Akero Therapeutics
AKRO
$187K 0.08%
7,526
-2,928
-28% -$82.3K
13 14
15
16 17

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2021 Portfolio in Review

As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.

Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.

  • Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
  • Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
  • Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
  • Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
  • Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
  • Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
  • Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.

Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.